Agitation is a common and hard-to-treat behavior change in Alzheimer disease. But recent trials of two existing agents suggest there’s hope for effective therapy without the need to resort to antipsychotics.
A breakthrough in the quest for a disease-modifying AD therapy is long overdue. Cleveland Clinic has developed a large, diverse and multisite clinical trials program in response. Here’s what drives our approach.
The FDA-approved lymphoma therapy bexarotene reduces brain amyloid in a mouse model of Alzheimer disease (AD). The BEAT-AD study is now studying it for the first time in humans with AD.